Tryptophan-associated eosinophilia-myalgia syndrome (L-TRP-EMS) is a newly described syndrome which occurred in epidemic fashion in the United States in the summer and fall of 1989. Epidemiologic data has linked the syndrome to intake of L-tryptophan (L-TRP) from one specific manufacturer, but the precise etiologic compound(s) must be established by replication of the syndrome in an appropriate animal model.
Introduction
We and others have recently described L-tryptophan-related eosinophilia myalgia syndrome (L-TRP-EMS)' in patients taking the amino acid L-tryptophan (L-TRP) for insomnia, depression, and other disorders (1) (2) (3) (4) . L-TRP-EMS is characterized initially by eosinophilia, myalgias, and edema, and subsequently by myositis, fasciitis, skin sclerosis, and peripheral neuropathy (2, 4, 5) . Occurrence ofthis syndrome reached epidemic proportions in the United States in the summer and fall of 1989 and by June 1990, at least 1,500 cases including 26 deaths had been reported (5, 6) .
The etiology and pathogenesis of the syndrome are not yet clear. However, several lines of evidence suggest that a contaminant(s) of L-TRP may trigger the syndrome. Epidemiologic studies have linked the development of L-TRP-EMS to ingestion of L-TRP from one manufacturer (7) (8) (9) . Retail lots of L-TRP from the implicated manufacturer that were associated with cases of L-TRP-EMS (case-associated L-TRP) were significantly more likely to have been produced from January through June, 1989 than were other lots from this manufacturer that were taken by asymptomatic control subjects (7) (8) (9) . It has been proposed that a contaminant(s) or a by-product of a specific manufacturing and/or purification process used by the implicated manufacturer is responsible for the epidemic occurrence of L-TRP-EMS (7) (8) (9) ). An animal model is important to identify a cause and effect relationship between contaminated L-TRP and the development of L-TRP-EMS and to define the pathogenesis of this complex syndrome.
In previous studies, we showed that female Lewis (LEW/N) rats are susceptible to many inflammatory diseases in response to a wide range ofinflammatory stimuli (10) (11) (12) . We suggested that the pattern of disease that LEW/N rats develop is related to the specific inflammatory stimulus to which they are exposed, while their general increased susceptibility to inflammation is related to a defect in induction ofthe counter-regulatory corticosteroid response (10) (11) (12) .
In this report, we show that LEW/N rats treated with implicated L-TRP but not with United States Pharmacopeia (USP) grade L-TRP or vehicle developed many of the specific features of L-TRP-EMS including perimyositis, fasciitis, and perivascular inflammation. Peripheral blood eosinophilia was not observed.
Methods
Animals. 36 6-wk-old female, virus antibody-free LEW/N rats weighing -100 g were obtained from Harlan-Sprague-Dawley (Indianapolis, IN). Rats were randomly divided into three groups of 12 animals, housed two per cage in microisolator cages in laminar flow units and were handled in laminar flow hoods only. The animal room was maintained at 18-260C and 40-70% humidity with a 12-h-on/12-h-off light cycle. Purified diet AIN-76A (13) containing 0.2% L-TRP was prepared by Dyets, Inc. (Bethlehem, PA) and provided in ceramic food bowls equipped with stainless steel lids and food followers. The rats were allowed free access to diet and distilled water throughout the study. Food consumption was measured weekly. Blood for total white blood cell and eosinophil counts was obtained by tail bleed into heparinized microcapillary tubes on the first day of the study and at weekly intervals therafter.
L-Tryptophan samples. Two samples of L-TRP were used in this study. One sample, "implicated L-TRP", was produced by the implicated manufacturer (7-9) in July 1989. The HPLC profile of the implicated L-TRP (Fig. I A) is similar to that of an L-TRP-EMS case-associated lot (Fig. I B) formulated by the implicated manufacturer in June 1989. The second sample used in this study was USP grade L-TRP from a nonimplicated manufacturer (Fig. 1 C) . The two L-TRP samples were blind-coded by the Centers for Disease Control and provided to the Food and Drug Administration, the National Institute of Mental Health, and the National Institute ofArthritis and Musculoskeletal and Skin Disease for animal testing. HPLC profiling. Methanol-water extracts were prepared and profiled by gradient elution from Partisil 5 ODS 3 columns (Whatman Inc., Clifton, NJ) using acetonitrile/water/trifluoroacetic acid (Fig. 1) .
Treatments. Suspensions of L-tryptophans were prepared in aqueous 0.5% methylcellulose ( 1758 thick sections of fresh-frozen muscle were processed for modified trichrome and muscle enzyme histochemistry as previously described (14) . Two of us independently viewed the biopsies in a blinded fashion on coded slides and scored for degree ofinflammation according to the number of counted inflammatory foci. The thickness of the fascia in the biopsies was measured directly from the slides, also in a blinded fashion, using a built-in micrometer.
Hind limbs for skin histology were removed and fixed in 10% neutral formalin. Lungs were inflated with 10% neutral formalin before fixation. The specimens were embedded in paraffin blocks, sectioned, and stained with hematoxylin and eosin by Metpath, Inc. (Rockville, MD).
Hematology. Total white blood cells were counted with a Coulter Counter. The values reported are the means oftwo determinations per sample. One observer, blinded to the identity ofthe groups, performed eosinophil counts as differentials of individual smears stained with Wright's stain. Lack of eosinophilia was corroborated by a second observer. Identification was based upon morphological and staining characteristics.
Biochemical assays. Plasma corticosterone levels were determined by radioimmunoassay (11) . Plasma kynurenine was assayed as described previously ( 15) .
In situ hybridization. A synthetic 48-base oligodeoxyribonucleotide probe for rat corticotropin-releasing hormone (16) (20) . For in situ hybridization, significance between control and experimental groups was determined by one-way analysis of variance and the Sheffe' F-test (21) utilizing commercially available software (StatView 2; Abacus Concepts, Inc., Berkeley, CA).
Results

Animals
By clinical observation, no consistent differences among groups were found during testing. No significant differences in weight gain (mean±SD) occurred among groups of rats after and implicated L-TRP: 55±6). Two of 12 rats in the USP grade and three of 12 rats in the implicated L-TRP-treated groups died as a result of gavage-related trauma (esophageal perforation). Autopsies confirmed the cause ofdeath in each case. For all animals, viral titers to rat coronavirus and sialodacryoadenitis virus, performed by ELISA (Microbiological Associates, Inc., Rockville, MD) at study termination were negative.
Pathology
Muscle and fascia. Muscle biopsy specimens from rats that received implicated L-TRP showed changes similar to those seen in cases of human L-TRP-EMS (2, 4, 22) . The characteristic findings include inflammatory infiltrates in the fascia and perimysial spaces consisting of mononuclear cells forming "islands" around small perimysial blood vessels (Fig. 2, a and b and Table I ). The lumen wall of some vessels was narrowed or obliterated by the infiltrating mononuclear cells (Fig. 2 c) . Eosinophils were not noted by light microscopy. In addition to these changes, in biopsies of rats treated with implicated L-TRP there was significant (P < 0.01) thickening ofthe fascia and the perimysial septae (Fig. 2, b and d, and Table I ). We also observed mild to moderate proliferation of perimysial connective tissue (Fig. 2 d) with fibroblastic proliferative changes on all biopsy specimens from the implicated L-TRP treatment group but only in three of 10 biopsies in each of the USP grade L-TRP and vehicle-treated groups. The number of counted fibroblastic cells in the perimysial tissue of the implicated L-TRP-treated group was not, however, significant compared to the other groups. A tendency for small fiber type grouping (up to 12 fibers) was also noted in the implicated L-TRP-treated animals as compared to some smaller size groupings (up to eight fibers) seen in other groups. This could be indicative of mild chronic denervation with reinnervation in the rats receiving implicated L-TRP. In these animals, mild inflammation was seen around occasional nerve trunks traveling along major interfascicular vessels. Rare sites of endomysial inflammation with phagocytosis of isolated muscle fibers especially in the periphery of the fascicles were also noted.
Lung/skin. In this study, lung histopathology showed no differences among the L-TRP-treated and vehicle-treated groups. Specifically, we found no evidence of perivascular infiltrates, vasculitis, or granulomatous changes. Sections of skin revealed no specific differences among groups.
Hematology
Total white blood cell counts and eosinophil counts were not significantly different among groups and did not change over the course of the study. Total white blood cell counts at day 0 and day 38 (mean X 103/mm3±SD) for the vehicle, USP grade L-TRP, and implicated L-TRP-treated groups, respectively, were 8.5±1.9 and 8.5±1.7; 7.8±1.2 and 8.2+1.2; and 6.7±1.2 and 7.8±1.5. The mean eosinophil count remained < 1% of 100 cells counted by manual differential for all groups at all weekly intervals and at study termination. The eosinophil counts for all animals was within the normal range (0-5%) throughout the study. . .
0~ '90
Plasma corticosterone Serum corticosterone levels (nanograms per milliliter, mean±SEM) for the vehicle group (173±41, n = 10) and USP grade L-TRP (157±38, n = 10) group were similar to those we have reported for LEW/N rats (11, 12) . The mean plasma corticosterone in the implicated L-TRP-treated group was lower than that of the other groups (91±36, n = 9), although this difference did not reach statistical significance (P < 0.21) by ANOVA.
In situ hybridization ofbrain section
Corticotropin releasing hormone mRNA levels (mean±SD expressed as a percentage of the vehicle-treated group) were significantly (P < 0.05) decreased in the hypothalamic paraventricular nucleus in the implicated L-TRP-treated group (88±8%) compared to the USP grade L-TRP-treated (101±11%) and vehicle-treated groups (100±8%). In the hip- pocampus, mineralocorticoid receptor mRNA levels were also reduced (P < 0.05) in the implicated L-TRP-treated group (82±1 1%) compared to the USP grade L-TRP (94±9%) and vehicle-treated (100±9%) groups. Glucocorticoid receptor mRNA levels were increased in both L-TRP-treated groups (128±11% and 1 10±1 1% for USP grade and implicated, respectively) as compared to control (100±13%), but the increase reached significance (P < 0.01) only in the USP grade L-TRP-treated group.
Plasma-L-kynurenine
Plasma L-kynurenine (L-KYN) levels in L-TRP-treated rats (micrometers, mean±SEM) were 5.86±0.91 in the implicated group and 5.62±0.70 in the USP group. They were significantly (P < 0.05) higher than the levels of vehicle-treated rats (3.26±0.36).
Discussion
The histologic changes in skin, fascia, muscle, and nerve in human L-TRP-EMS show a characteristic distribution of inflammatory cell infiltrates and fibrosis (2, 4, 22) . We have shown that specific and quantitatively significant perimysial and fascial changes develop in female LEW/N rats treated with implicated L-TRP but not in those treated with USP grade L-TRP or vehicle. There were no specific histologic changes and no differences between groups in the lung or skin. Peripheral blood eosinophilia was not seen, nor were eosinophils observed by light microscopy in the affected tissues. The lack of eosinophilia may relate to experimental design or a species difference, although eosinophilia does develop in rats used in experimental studies of allergic, parasitic, and nutritional diseases (23) (24) (25) (26) . The moderate degree of inflammation could be due to the duration of the study, species related differences in inflammatory responses, a dose-response effect dependent upon the amount of unknown contaminant(s) in the implicated L-TRP used, or the lack of peripheral eosinophilia, if eosinophil degranulation products play a role in amplifying the inflammatory and/or fibrotic response (3, 4) . Implicated L-TRP-treated rats showed significantly lower hypothalamic corticotropin releasing hormone mRNA and hippocampal mineralocorticoid receptor mRNA levels, as well as a trend to lower plasma corticosterone levels, compared to the other groups of rats. A contaminant(s) structurally related to L-TRP with serotonin antagonist or benzodiazepine agonist activity could theoretically suppress the HPA axis (27) (28) (29) (30) . In light of our previously proposed hypothesis that enhanced susceptibility to inflammatory disease in the LEW/N rat is related to their deficient HPA axis-related counter-regulation of the inflammatory response (2, 10-12), a contaminant(s), with suppressive effects on the HPA axis, could amplify its own or other contaminant(s)' proinflammatory effects. In this regard the implicated peak 97 (Fig. 1) (8, 9 ) has been tentatively identified as di-L-tryptophan aminal of acetaldehyde (8) which could decompose to 1-methyl-1,2,3,4-tetrahydro-B-carboline-3-carboxylic acid (8) a compound which could potentially have benzodiazepinelike activity (31) .
In the present study, the increases in plasma L-KYN concentrations in the rats 24 h after the last L-TRP dose are consistent with the established effects of chronic loads of L-TRP on the kynurenine pathway (32) . Further studies are required to define the role of these metabolites in the disease process in light of evidence that elevation of L-TRP metabolites can promote fibroblast proliferation (33, 34) .
The clinical and histologic characteristics of L-TRP-EMS in humans are similar to a syndrome following administration of L-5-hydroxytryptophan and carbidopa (34), to other idiopathic inflammatory diseases of fibrous connective tissue, particularly eosinophilic fasciitis (35, 36) , and to those observed in the toxic oil syndrome (TOS) that occurred in epidemic form in Spain in the spring of 1981 (37, 38). Epidemiologic studies of TOS linked the syndrome to adulterated rapeseed oil which was used as a cooking oil. Although the development of the syndrome was epidemiologically associated with certain impurities in the oil (e.g., oleyl anilide) (39), the etiology of TOS remains uncertain because an animal model reproducing the syndrome was never identified.
Animal models of human diseases allow the analysis of underlying etiologic and pathogenic events and are critical in establishing a cause-and-effect relationship between a putative etiologic agent and the development of a set of specific clinical symptoms and signs. Our study provides evidence that the female Lewis rat is a suitable animal in which to study the effects of implicated L-TRP as well as the complex factors involved in the pathogenesis of inflammatory, fibrosing syndromes of muscle and fascia. Further studies are required to identify the chemical structure ofthe contaminant(s) responsible for initiation of inflammation in L-TRP-EMS, as well as to determine whether such compounds can induce the syndrome in the absence of large doses of L-TRP. Finally, this animal model may be useful for testing potential treatment modalities for the human eosinophilia-myalgia syndrome.
